UK Registered Veterinary Retailer

Nobivac Lepto 2

Nobivac Lepto 2
Single Dose Lepto 2 for injection
Single Vial Lepto 4 for Injection

  • Single Dose Lepto 2 for injection £3.40
  • Single Vial Lepto 4 for Injection £8.50

Selection of 2 products from

£3.40 to £8.50

Description

Nobivac Lepto 2

Species:

Dogs

Therapeutic indication:

Immunological veterinary medical products: For dogs

Active ingredient:

Vaccine Antigens

Product:

Nobivac® Lepto 2

Product index:

Nobivac Lepto 2

Qualitative and quantitative composition

Active ingredient per dose of 1 ml Inactivated Leptospira interrogans serogroup - Canicola; strain Ca-12-000: 957 - 1676 ELISA Units* - Icterohaemorrhagiae; strain 820K: 625 - 1335 ELISA Units * Antigen mass ELISA Units, in vitro potency test according to Ph.Eur. monograph 0477. Excipients Preservative: Thiomersal 0.1 mg. For a full list of excipients see section "Pharmaceutical particulars".

Pharmaceutical form

Aqueous suspension for injection.

Clinical particulars

Target species

Dogs.

Indications for use

For active immunisation of dogs to reduce infection with Leptospira interrogans serogroup canicola and Leptospira interrogans serogroup icterohaemorrhagiae. Specific claims: The duration of immunity induced by the vaccine was established as at least one year. Nobivac Lepto 2 significantly reduces the number of animals which develop a urinary tract infection which can predispose to development of a carrier condition after L. canicola and L. icterohaemorrhagiae infection.

Contra-indications

Only healthy dogs should be vaccinated.

Special warnings for each target species

The vaccine may not be effective in dogs incubating the disease at the time of vaccination. Animals that have received the corresponding anti-serum or immunosuppressive drugs should not be vaccinated until an interval of at least 4 weeks has elapsed. A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.

Special precautions for use

None. Operator warnings: None.

Adverse reactions

A local reaction of limited size may occur during the first few days after vaccination. After subcutaneous administration with the DHPPi, Pi, Parvo-C and/or rabies vaccines of the Nobivac series a diffuse swelling may be observed at the injection site in most puppies. Occasionally this swelling may be hard and painful but this will diminish gradually and will disappear after 2 - 3 weeks. In the rare event of a hypersensitivity reaction following vaccination, administer an antihistamine, corticosteroid or adrenaline, without delay and by the most immediate route.

Use during pregnancy, lactation or lay

The vaccine has been shown to be safe for use in pregnant bitches which have previously been vaccinated with Nobivac Lepto 2.

Interactions

Safety and/or efficacy data are available which demonstrate that this vaccine can be mixed with live vaccines from the Nobivac range containing Canine distemper virus (strain Onderstepoort), Canine adenovirus type 2 (strain Manhattan LPV3), Canine parvovirus (strain 154) and/or Canine parainfluenza virus (strain Cornell). Safety and/or efficacy data are available which demonstrate that this vaccine can be administered the same day but not mixed with the inactivated rabies (strain Pasteur RIV) vaccine for the Nobivac range.

Amounts to be administered and administration route

The contents of one vial (1 ml) should be administered by subcutaneous injection. Allow the vaccine to reach room temperature (15 °C - 25 °C) before use. Sterile injection equipment should be used. Primary course vaccination: All dogs not previously vaccinated should be vaccinated twice 2 - 4 weeks apart. Puppies should be at least 6 weeks of age before they receive the first vaccination. Booster vaccination A single annual booster dose is recommended. Nobivac Lepto 2 may be used to reconstitute Nobivac DHPPi, DHP, Pi or Parvo-C as indicated in the appropriate package leaflets. For more detailed advice on vaccination programmes and how the product may be used in conjunction with other Nobivac dog vaccines in specific circumstances contact the company direct or refer to the support literature.

Overdose

No particular symptoms at double dose (see section “ Adverse reactions”).

Withdrawal periods

Not applicable.

Pharmacological particulars

Immunological properties: ATC Vet code: QI07AB01 Strains of Leptospira interrogans serogroups Canicola and Icterohaemorrhagiae are responsible for leptospirosis in dogs. The active ingredients of the vaccine Leptospira interrogans Canicola; strain Ca-12-000 and Leptospira interrogans Icterohaemorrhagiae; strain 820K stimulate active immunity against these serogroups.

Pharmaceutical particulars

Excipients

Stabiliser solution and thiomersal.

Major incompatibilities

Do not mix with any other medicinal product except with the vaccines indicated in section “ Interactions”.

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 21 months. Shelf life after first opening of the immediate packaging: 10 hours.

Special precautions for storage

Store at 2 °C - 8 °C. Protect from light. Do not freeze.

Immediate packaging

Carton box with 1, 10 or 50 vials of glass type I (Ph.Eur.) containing 1 ml or 10 ml or plastic box with 10 or 50 vials of glass type I (Ph.Eur.) containing 1 ml closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap. Not all presentations may be marketed.

Disposal

Any unused veterinary medicinal product or waste material derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Marketing Authorisation Number

Vm 01708/4360

Significant changes

Date of the first authorisation or date of renewal

31 May 2002.

Date of revision of the text

20 January 2016.

Any other information

For animal treatment only. Keep out of the sight and reach of children.

Legal category

Legal category: POM-V

GTIN

GTIN description:Nobivac Lepto 2 10x1ds: GTIN:08713184144133, GTIN description:Nobivac Lepto 2 50x1ds: GTIN:08713184027665

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

Single Dose Lepto 2 for injection

Nobivac DHPPi, Lyophilisate for Suspension for Injection for Dogs

Qualitative and quantitative composition

Each dose of 1 ml contains:

Active substances:

Live canine distemper virus (CDV), strain Onderstepoort ≥ 104.0 TCID50*

Live canine adenovirus type 2 (CAV2), strain Manhattan LPV3 ≥ 104.0 TCID50*

Live canine parvovirus (CPV), strain 154 ≥ 107.0 TCID50*

Live canine parainfluenza virus (CPi), strain Cornell ≥ 105.5 TCID50*

* TCID50 = median Tissue Culture Infective Dose

For the full list of excipients, see the Pharmaceutical Particulars section.

Pharmaceutical form

Lyophilisate for suspension for injection. Off-white or cream-coloured pellet.

Clinical particulars

Target Species:

Dogs.

Indications for use:

For active immunisation of dogs to prevent mortality and clinical signs caused by canine distemper virus infection. To reduce clinical signs of infectious hepatitis and viral excretion due to canine adenovirus type 1 infection. To prevent mortality, clinical signs and viral excretion following canine parvovirus infection. To reduce clinical signs and viral excretion caused by canine parainfluenza virus infection and to reduce clinical signs of respiratory disease and viral excretion following adenovirus type 2 infection.

Onset of immunity

1 week for canine distemper virus, canine adenovirus and canine parvovirus vaccine components

4 weeks for canine parainfluenza virus vaccine component

Duration of immunity

At least three years for the canine distemper virus, canine adenovirus and canine parvovirus vaccine components.

The duration of immunity for the canine parainfluenza virus component has not been demonstrated, but an anamnestic response is produced in dogs given a revaccination one year after basic vaccination. Annual revaccination with the canine parainfluenza virus vaccine component is recommended.

Contra-indications:

Only healthy dogs should be vaccinated. The vaccine may not be effective in dogs incubating the disease at the time of vaccination.

Some animals may be immunologically incompetent and fail to respond to vaccination. Animals that have received the corresponding anti-serum or immunosuppressive drugs should not be vaccinated until an interval of at least 4 weeks has elapsed.

Special warnings for each target species:

The efficacy of the CDV, CAV2, CPV and CPi components of the vaccine may be reduced due to maternal antibody interference. However, the vaccine has been proved to be of benefit against virulent challenge in the presence of maternal antibody levels to CDV, CAV2, CPV and CPi that are likely to be encountered under field conditions.

Special precautions for use:

Only healthy dogs should be vaccinated.

The canine parvovirus vaccine strain may be shed at very low levels for up to 8 days after inoculation. However there is no evidence of any reversion to virulence of the vaccine strain and therefore no need to separate unvaccinated dogs from contact with recently vaccinated individuals.

Operator warnings:

In the case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Adverse Reactions:

In very rare cases, a diffuse swelling, up to 5 mm in diameter, may be observed at the site of injection. Occasionally this swelling may be hard and painful and last for up to 3 days post injection.

In the very rare event of a hypersensitivity reaction occurring following vaccination, administer an antihistamine, corticosteroid or adrenaline, without delay and by the most immediate route.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)

- common (more than 1 but less than 10 animals in 100 animals)

- uncommon (more than 1 but less than 10 animals in 1,000 animals)

- rare (more than 1 but less than 10 animals in 10,000 animals)

- very rare (less than 1 animal in 10,000 animals, including isolated reports).

Use during pregnancy or lactation:

Can be used in pregnant bitches which have previously been vaccinated with the CDV (strain Onderstepoort), CAV2 (strain Manhattan LPV3), CPV (strain 154) and CPi (strain Cornell) antigens included in the Nobivac vaccine series.

Interactions:

Safety and efficacy data (viral excretion) are available which demonstrate that this vaccine can be mixed and administered with the inactivated vaccines of the Nobivac series against canine leptospirosis caused by all or some of the following serovars: L. interrogans serogroup Canicola serovar Canicola, L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis serovar Bratislava, and L. kirschneri serogroup Grippotyphosa serovar Bananal/Liangguang.

The product information of the relevant Nobivac vaccines should be consulted before administration of the mixed product. When mixed with Nobivac leptospirosis vaccines at annual revaccination, it has been established that there is no interference with the anamnestic response induced by the injectable canine parainfluenza virus component.

After administration with one of the leptospirosis vaccines, a mild and transient increase in body temperature (≤ 1°C) may occur for a few days after vaccination, with some pups showing less activity and/or a reduced appetite. A small transient swelling (≤ 4 cm), which can occasionally be firm and painful on palpation, may be observed at the site of injection. Any such swelling will either have disappeared or be clearly diminished by 14 days post-vaccination.

After mixed administration of an overdose of Nobivac DHPPi and an overdose of the leptospirosis vaccines of the Nobivac series, transient local reactions such as diffuse to firm swellings from 1 to 5 cm in diameter may be observed, usually these will persist no longer than 5 weeks, however some may take a little longer to completely disappear.

When Nobivac DHPPi is used with any of the other Nobivac vaccines referred to above, the minimum vaccination age for each vaccine must be taken into account such that at the time of vaccination, the dogs are at or older than the oldest minimum vaccination age for the individual vaccines.

Safety and efficacy data are available which demonstrate that this vaccine can also be administered on the same day with Nobivac Solvent or Nobivac Rabies. These can be used to reconstitute the freeze-dried Nobivac DHPPi.

No information is available on the compatibility of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Amounts to be administered and administration route:

One ml solvent or 1 ml (1 dose) of inactivated vaccine (as specified in the section on ‘Interactions’) must be used to reconstitute the freeze-dried Nobivac DHPPi vaccine.

The contents of one vial of reconstituted vaccine should be injected subcutaneously.

Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation.

Primary course vaccination:

A single injection should establish active immunity to canine distemper, infectious canine hepatitis and disease caused by canine parvovirus infection in dogs of 10 weeks of age or older. Where earlier protection is required a first dose may be given to puppies from 6 weeks of age, but because maternally derived passive antibody can interfere with the response to vaccination a final dose at 10 weeks of age or older is generally recommended. For an optimal response to the parainfluenza component, animals should be vaccinated twice, 2-4 weeks apart with the final vaccination at 10 weeks of age or more.

The event that the initial primary course dose of Nobivac DHPPi is delayed to 10 weeks of age or older, a single dose of Nobivac Pi at 12 weeks of age or older should suffice to establish immunity for this component.

Booster vaccination:

It is recommended that dogs be revaccinated with canine distemper virus, canine adenovirus and canine parvovirus every 3 years and against canine parainfluenzavirus every year.

It was not possible to produce clinical signs of kennel cough by parainfluenza challenge in adult dogs and duration of immunity could not therefore be demonstrated, but an anamnestic response was seen in dogs given a booster one year after primary vaccination. Revaccination against parainfluenza is recommended prior to exposure to high risk environments (such as kennelling, showing or mixing with dogs of unknown vaccination history).

Further information

Experience has shown that the maternal antibody status of pups within a litter varies greatly and reliance should not be placed on serological examination of the bitch alone.

A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. The immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.

Overdose:

Similar in nature to that from a single dose (see section on 'Adverse Reactions'). In some dogs the swelling may be more painful or may be observed for a longer period.

Withdrawal periods:

Not applicable.

Pharmacological particulars

ATC Vet Code: QI07AD04

Pharmacotherapeutic group: live viral vaccine for dogs.

The vaccine contains attenuated antigens to stimulate active immunity against canine distemper, canine parvovirus disease, canine infectious hepatitis caused by canine adenovirus type 1 and respiratory disease caused by canine adenovirus type 2 and canine parainfluenza virus.

Pharmaceutical particulars

Excipients:

Sorbitol, Hydrolised Gelatine, Pancreatic digest of casein, Di-Sodium phosphate 12 H2O, Water for injections.

Major incompatibilities:

Do not mix with any other veterinary medicinal products, except with Nobivac Solvent, or other Nobivac dog vaccines mentioned in the Interactions section.

Shelf-life:

Shelf life of the veterinary medicinal product as packaged for sale: 2 years

Shelf life after reconstitution according to directions: 30 minutes

Special precautions for storage:

Store in a refrigerator (2 °C - 8 °C).

Do not freeze.

Protect from light.

Care should be taken to avoid prolonged or repetitive exposure to high ambient temperatures following withdrawal from the refrigerator prior to use - in hot summer conditions vaccine potency can be severely reduced within a few hours.

Immediate packaging:

Clear, Glass Type I (Ph.Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap. Cardboard or plastic boxes containing 10 or 50 vials

Disposal:

Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.

Marketing Authorisation Holder (if different from distributor)

Marketing Authorisation Number

Vm 01708/4359

Date of the first authorisation or date of renewal

20 October 2005

Date of revision of the text

09 February 2017

Any other information

For animal treatment only. Keep out of the sight and reach of children.

Legal category

Single Vial Lepto 4 for Injection

Nobivac L4, suspension for injection for dogs

Qualitative and quantitative composition

Each dose of 1 ml contains:
Active substances:
Inactivated Leptospira strains:
L. interrogans serogroup Canicola
serovar Portland-vere (strain Ca-12-000) | 3550-7100 U*
L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni
(strain Ic-02-001) | 290-1000 U*
L. interrogans serogroup Australis
serovar Bratislava (strain As-05-073) | 500-1700 U*
L. kirschneri serogroup Grippotyphosa serovar Dadas strain
Gr-01-005) | 650-1300 U*
* Antigenic mass ELISA units.Excipient: Thiomersal 0.1 mg.

For a full list of excipients, see section "Pharmaceutical particulars".

Pharmaceutical form

Suspension for injection. Colourless suspension.

Clinical particulars

Target species

Dogs.

Indications for use, specifying the target species

For active immunisation of dogs against:

L. interrogans serogroup Canicola serovar Canicola to reduce infection and urinary excretion.

L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni to reduce infection and urinary excretion.

L. interrogans serogroup Australis serovar Bratislava to reduce infection.

L. kirschneri serogroup Grippotyphosa serovar Bananal/Lianguang to reduce infection and urinary excretion.

Onset of immunity: 3 weeks.

Duration of immunity: 1 year.

Contraindications

None.

Special warnings

Vaccinate only healthy animals.

Special precautions for use

Special precautions for use in animals

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Avoid accidental self-injection or contact with the eyes. In case of ocular irritation seek medical advice immediately and show the package leaflet or the label to the physician.

Adverse reactions (frequency and seriousness)

A mild and transient increase in body temperature (£ 1 °C) has been observed very commonly in clinical studies for a few days after vaccination, with some pups showing less activity and/or a reduced appetite. A small transient swelling at the site of injection (£ 4 cm), which can occasionally be firm and painful on palpation, has been observed very commonly in clinical studies. Any such swelling will either have disappeared or be clearly diminished by 14 days post-vaccination.

In very rare cases, clinical signs of immune-mediated haemolytic anaemia, immune-mediated thrombocytopenia, or immune-mediated polyarthritis have been reported. In very rare cases a transient acute hypersensitivity reaction may occur. Such reactions may evolve to a more severe condition (anaphylaxis), which may be life-threatening. If such reactions occur appropriate treatment is recommended.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Use during pregnancy, lactation or lay

Can be used during pregnancy.

Interaction with other medicinal products and other forms of interaction

Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with vaccines of the Nobivac series containing canine distemper virus, canine adenovirus type 2, canine parvovirus and/or canine parainfluenza virus components for subcutaneous administration. The product information of the relevant Nobivac vaccines should be consulted before administration of the mixed product. When mixed with these Nobivac vaccines, the demonstrated safety and efficacy claims for Nobivac L4 are no different from those described for Nobivac L4 alone. When mixed with Nobivac vaccines containing canine parainfluenza virus at annual revaccination, it has been established that there is no interference with the anamnestic response induced by the injectable canine parainfluenza virus component.

Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with vaccines of the Nobivac series containing Bordetella bronchiseptica and/or parainfluenza virus components for intranasal administration.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Amounts to be administered and administration route

Subcutaneous use.

Before use, ensure that the vaccine is at room temperature (15°C - 25°C).

Administer two vaccinations of 1 dose (1 ml) of vaccine with an interval of 4 weeks to dogs from 6 weeks of age onwards.

Vaccination scheme:

Basic vaccination: The first vaccination can be administered from 6 to 9(*) weeks of age and the second vaccination from 10 to 13 weeks of age.

Revaccination: Dogs should be re-vaccinated annually with one dose (1 ml) of vaccine.

(*) In case of high level of MDA, first vaccination is recommended at 9 weeks of age.

For simultaneous use, 1 dose of a Nobivac vaccine containing canine distemper virus, canine adenovirus type 2, canine parvovirus, and/or canine parainfluenza virus components should be reconstituted with 1 dose (1 ml) of Nobivac L4. The mixed vaccines should be at room temperature (15°C - 25°C) before they are administered by subcutaneous injection.

Overdose (symptoms, emergency procedures, antidotes), if necessary

No adverse reactions other than those mentioned in section "Adverse Reactions" were observed after the administration of a double dose of vaccine. However, these reactions may be more severe and/or last longer. For example, local swelling, which can be up to 5 cm in diameter and which may take over 5 weeks to completely disappear, may be observed at the site of injection.

Withdrawal period

Not applicable.

Pharmacological particulars

Immunological properties

Pharmacotherapeutic group: Immunologicals for Canidae, inactivated bacterial vaccines.

ATCvet code: QI07AB01.

To stimulate active immunity in dogs against L. interrogans serogroup Canicola serovar Canicola, L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis serovar Bratislava, and L. kirschneri serogroup Grippotyphosa serovar Bananal/Lianguang.

In vitro and in vivo data in non-target species suggests that the vaccine may provide a degree of cross-protection against L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae and L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa.

Pharmaceutical particulars

List of excipients

Thiomersal

Sodium chloride

Potassium chloride

Disodium phosphate dihydrate

Potassium dihydrogen phosphate

Water for injections

Major incompatibilities

Do not mix with any other veterinary medicinal product except those mentioned in section 4.8.

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 21 months.

Shelf life after first opening the immediate container: 10 hours.

Shelf life after reconstitution of Nobivac vaccines according to directions: 45 mins.

Special precautions for storage

Store in a refrigerator (2 °C – 8 °C).

Do not freeze.

Protect from light.

Nature and composition of immediate packaging

Type I glass vial of 1 ml (1 dose) or 10 ml (10 doses) closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap.

Pack sizes:

Plastic box with 5, 10, 25 or 50 vials of 1 ml (1 dose).

Cardboard box with 1 vial of 10 ml (10 doses).

Not all pack sizes may be marketed.

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Marketing Authorisation Holder (if different from distributor)

Intervet International B.V.

Wim de Körverstraat 35

5831 AN Boxmeer

The Netherlands

Marketing Authorisation Number

EU/2/12/143/001-005

Date of the first authorisation or date of renewal

13 July 2017.

Date of revision of the text

13 March 2017.

Any other information

For animal treatment only. Keep out of the sight and reach of children.

Legal category

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.

Delivery of aerosols

Due to restrictions aerosols can't be sent by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews (3)

Q & A

Below are some recent questions we've received regarding Nobivac Lepto 2, including answers from our team.

1 March 2016 at 9:42am

Do I get card to put batch etc on for use in kennels

Ruth

Will I get card to prove dosage and batch for proof of cover for kennels

  • Non-Executive Director

If you ask separately for a vaccine card we can send one with your order at no extra charge. You have to do this or you will not get one. The vaccine itself comes in small bottles with a peel-off label which you can stick on the vaccine card. It states the name of the vaccine, the batch number and the expiry date (= use-by date for giving the vaccine, not how long the immunity lasts for). There is a place on the card for the person who gave the vaccine to sign. Normally your vet would sign here, but a vet should not sign if they did not give the vaccine. You can sign it yourself and as long as you do not put any false qualifications there, then the vaccine record card is correct, genuine and can be used. You must not pretend to be a vet, or that is actually against the law. It would be up to the kennels to decide if they wanted to accept a record card signed by you, though they might well not notice who signed it in fact.

12 August 2015 at 11:12am

Nobivac l4

lesey michael

does lepto4 have to be given 4weeks apart. what time scale is there between injections

  • Non-Executive Director

Ideally it should be 4 weeks between injections which is on the data sheet. Some vets still use the same protocol as for Lepto 2, ie a minimum of 2 weeks and a maximum of 4 weeks between the two injections for an initial course. My guess is that this would be effective but it is not on the data sheet. early completion of the course to facilitate early socialisation and habituation is a factor to consider.